For biotechnology companies, drug development is a race against time, capital and scientific uncertainty. Outsourcing critical preclinical activities, such as pharmacology, toxicology and translational efficacy studies, to a Contract Research Organization (CRO) is an established strategy to move faster while spreading risk.
The same decision carries a downside. A provider that cannot produce reliable data costs a program its timeline, and occasionally its clinical future, well after the invoice has been paid.
So how do Biotech teams separate a capable preclinical CRO from a persuasive one? The criteria below are the ones worth checking before a study plan is signed. They work as a risk-avoidance checklist, and as a way to judge whether a provider will still be the right partner two or three years from now.
1. Core Technology Platforms and Disease Model Capabilities: Proven Science or Just Marketing?
The translational relevance of preclinical research is a major determinant of clinical success. Many CROs advertise "animal models"; the difference that matters is whether the models themselves:
- faithfully reproduce human disease physiology,
- exhibit consistent and reproducible phenotypes, and
- have been thoroughly validated with multidimensional endpoints.
A model that answers all three gives a sponsor something to argue with at the regulatory stage. A model that answers none of them gives a slide deck.
A common pitfall is a library built only on traditional rodent models, or one that has not been refreshed in years. Rodent-only data often carry limited predictive power for complex human disease, and efficacy read out that way can send a program in the wrong direction before anyone notices.
What to look for instead is deep expertise in NHP Pharmacology. NHPs share high genetic, physiological and pathological similarity with humans, which makes them a practical source of clinically predictive data, especially in CNS disorders, immunology, respiratory diseases, metabolic disorders and ophthalmology. That similarity is not a slogan. It is the reason a pharmacological response seen in the animal can be read as a plausible response in patients.
Prisys Biotech works on NHP translational science as its main line, and the platform reflects that focus.
- Over 40 validated NHP disease models, covering respiratory, metabolic, immuno-inflammatory (e.g., rheumatoid arthritis), CNS, ophthalmology and other therapeutic areas
- 57 technology patents and IP assets related to NHP modeling and translational research, with validation built on several parameter families:
- disease incidence
- behavioral and clinical scoring
- imaging readouts (MRI, PET, CT)
- biomarkers such as CRP, cytokines, metabolic indicators
Read together, those checks are what make a dataset usable at filing: stability across animals, reproducibility across studies, and endpoints a reviewer can follow. They are also what allows such data to support IND submissions.
2. Facility Scale and Technical Infrastructure: Small Workshop or Industrial-Grade Platform?
Large-animal studies, and NHP research in particular, need industrial-grade infrastructure, strict biosecurity, and imaging and monitoring equipment that is maintained and calibrated. Facility quality directly determines:
- the types of studies that can be executed,
- the precision of measurements, and
- overall study reproducibility and compliance with global standards.
Housing, surgical space and imaging access are usually the constraints that decide whether a protocol is workable at all. Sponsors rarely see them until a study is under way, which is why a site visit or a documented facility description tells you more than a capacity claim in a proposal.
3. Accreditation and Quality Management Systems: Self-Declared Competence or Internationally Recognized Standards?
Accreditations give sponsors an outside check on a CRO's scientific competence, quality control practices and ethical standards. Where globally recognized certifications are missing, the data generated may face obstacles during multinational regulatory submissions and global clinical trial applications.
The pitfall here is easy to miss: overlooking a CRO's international accreditations, such as AAALAC or ISO certifications, then discovering that a study does not meet global regulatory expectations for ethics, Animal-Welfare and data quality.
What to verify is full AAALAC International accreditation, the reference point most sponsors use for animal care and use worldwide. Alongside it, check for:
- valid and compliant Animal Use Licenses,
- a functioning Institutional Animal Care and Use Committee (IACUC) system,
- ISO 9001-based quality management systems, and
- appropriate biosafety-level infrastructure (e.g., BSL-2).
Prisys Biotech holds full AAALAC International accreditation, maintains all legally required animal use licenses, and operates under a stringent IACUC review framework. Its facilities meet BSL-2 standards, and its quality management system follows ISO 9001 principles.
Those certifications do two things for a sponsor. They confirm that animal care, ethics review and data handling are audited by someone other than the provider, and they remove a familiar source of delay when an IND-enabling package has to satisfy more than one regulator.
4. Scientific Team and Project Expertise: Training Ground for Beginners or Guided by Real Experts?
Preclinical research relies heavily on the scientific judgment, technical proficiency and accumulated project experience of the research team. An experienced team understands the nuances of disease biology, can design efficient study plans, and can troubleshoot complex problems as they appear mid-study.
Being persuaded by a sales presentation while neglecting the actual scientific team is the usual mistake. Prior project record and disease-area expertise decide whether a difficult model becomes a working assay or a repeated failure, and a team without that background will struggle with high-complexity studies or with ambiguous results.
Worth examining: the background and seniority of core scientific personnel, average years of industry experience, specialized expertise in relevant therapeutic areas (e.g., immunology, CNS, inflammation), and successful collaborations with pharmaceutical companies.
Prisys Biotech brings together an interdisciplinary team of returnee scientists, veteran medical specialists, veterinarians and highly trained technical staff. Its Founder and Chief Scientific Officer previously served as Senior Research Director, where he moved programs in antithrombotic, antiviral and other therapeutic areas into clinical development. That cross-functional R&D experience carries directly into how complex translational programs are supported today.
The broader scientific team averages over 15 years of hands-on experience in NHP research. Support runs across the whole outsourcing workflow, from early consultation and study design to data interpretation and regulatory-ready reporting.
FAQ: Choosing the Right Preclinical CRO
1. Why are NHP models critical for certain therapeutic areas?
NHPs share high homology with humans in immune, metabolic, neurological and respiratory systems. That makes them hard to replace when evaluating biologics, gene therapies, CNS therapeutics and other modalities that require high translational fidelity.
2. How can I determine whether a CRO's disease models are truly validated?
Ask for:
- published data or validation reports
- biomarker and imaging evidence
- reproducibility metrics
- historical control datasets
- regulatory submission experience (e.g., IND-enabling packages)
3. What infrastructure should a high-quality NHP CRO possess?
Industrial-scale animal facilities, GLP/AAALAC-compliant operations, imaging systems (MRI/PET/CT), telemetric monitoring, BSL-2/3 capabilities, and experienced veterinary and pathology teams.
4. Does working with an NHP-focused CRO extend timelines or increase cost?
Not necessarily. High-fidelity models reduce downstream development failures, which saves time and investment by improving translational accuracy from preclinical to clinical stages.
5. What differentiates Prisys Biotech from traditional preclinical CROs?
Prisys combines:
- specialized NHP expertise,
- validated models across 40+ diseases,
- imaging and biomarker platforms, and
- experience supporting global IND submissions.
The result is data generation that holds up for complex therapeutic programs, from model selection through to the report a regulator receives.
